Tocilizumab Subcutaneous Injection (RoActemra®)
A Contract Award Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (‘NSS’)
- Source
- OJEU
- Type
- Framework (Supply)
- Duration
- not specified
- Value
- £25M
- Sector
- HEALTH
- Published
- 08 Feb 2021
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014
2 buyers
- NHS National Services Scotland NSS Edinburgh
1 supplier
- Roche Products Welwyn Garden City
Description
The supply of Tocilizumab Subcutaneous Injections (RoActemra®) to NHS Scotland which used to treat licensed indications. This medicine is not being procured to treat Covid-19.
Total Quantity or Scope
Supply of Tocilizumab Subcutaneous Injections (RoActemra®) to NHS Scotland. The Authority has awarded this framework as a single supplier framework per line.
Award Detail
| 1 | Roche Products (Welwyn Garden City)
|
Award Criteria
| PRICE | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Award on basis of price.
Legal Justification
The patent for Tocilizumab (RoActemra®) has expired December 2020, there is no known competition that has entered the UK market place and there is none anticipated for the initial duration of the framework agreement.
Other Information
The total value in Sections II.1.7) and V.2.4) refers to the twenty four (24) months initial period with the option to extend by up to a total period of twenty four (24) months. (SC Ref:642715)
Reference
- OJEU 065594-2021